We are live on ! Find out more
PGNX

Progenics Pharmaceuticals Inc
PGNX

Delisted

PGNX was delisted on the 19th of June, 2020.

Back to rankings

76 hedge funds and large institutions have $219M invested in Progenics Pharmaceuticals Inc in 2014 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 28 increasing their positions, 25 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

21% more call options, than puts

Call options by funds: $948K | Put options by funds: $781K

12% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 25

3% more capital invested

Capital invested by funds: $213M → $219M (+$5.72M)

13% less funds holding

Funds holding: 87 → 76 (-11)

55% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 20

Holders
76
Holders Change
-11
Holders Change %
-12.64%
% of All Funds
2.18%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
9
Increased
28
Reduced
25
Closed
20
Calls
$948K
Puts
$781K
Net Calls
+$167K
Net Calls Change
+$123K

Top Buyers

Rank Fund Capital Flow
1
BC
Broadfin Capital
New York
+$4.01M
2
HCMT
Highland Capital Management (Texas)
Texas
+$785K
3
Millennium Management
Millennium Management
New York
+$505K
4
JG
Jefferies Group
New York
+$496K
5
PFC
Phocas Financial Corp
California
+$482K

Top Sellers

Rank Fund Capital Flow
1
TCA
Taconic Capital Advisors
New York
-$3.21M
2
Franklin Resources
Franklin Resources
California
-$2.6M
3
NI
Numeric Investors
Massachusetts
-$1.46M
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$1.26M
5
HCM
Highbridge Capital Management
New York
-$708K
Name Holding Trade Value Shares
Change 		Change in
Stake
Millennium Management
26
Millennium Management
New York
$570K +$505K +132,156 New
JG
27
Jefferies Group
New York
$560K +$496K +130,000 New
California State Teachers Retirement System (CalSTRS)
28
California State Teachers Retirement System (CalSTRS)
California
$547K +$11.1K +2,900 +2%
Bank of America
29
Bank of America
North Carolina
$504K -$72.3K -18,944 -14%
BCM
30
Bridgeway Capital Management
Texas
$492K +$148K +38,700 +51%
PPA
31
Parametric Portfolio Associates
Washington
$469K +$3.62K +949 +0.9%
Susquehanna International Group
32
Susquehanna International Group
Pennsylvania
$457K -$49K -12,829 -11%
Charles Schwab
33
Charles Schwab
California
$457K – – –
TA
34
Teachers Advisors
New York
$438K -$31.4K -8,214 -7%
AllianceBernstein
35
AllianceBernstein
Tennessee
$392K +$132K +34,529 +61%
TC
36
TFS Capital
Pennsylvania
$384K -$230K -60,202 -40%
Jacobs Levy Equity Management
37
Jacobs Levy Equity Management
New Jersey
$381K -$193K -50,600 -36%
RhumbLine Advisers
38
RhumbLine Advisers
Massachusetts
$344K +$107K +27,914 +54%
ZIM
39
Zacks Investment Management
Illinois
$333K +$295K +77,322 New
ProShare Advisors
40
ProShare Advisors
Maryland
$327K -$175K -45,842 -38%
MLICM
41
Metropolitan Life Insurance Company (MetLife)
New York
$305K – – –
HK
42
Horizon Kinetics
New York
$290K – – –
Goldman Sachs
43
Goldman Sachs
New York
$255K -$31.9K -8,352 -12%
SAM
44
Symphony Asset Management
California
$253K +$224K +58,691 New
NFA
45
Nationwide Fund Advisors
Ohio
$234K +$6.58K +1,722 +3%
CS
46
Credit Suisse
Switzerland
$199K -$391K -102,282 -69%
State Board of Administration of Florida Retirement System
47
State Board of Administration of Florida Retirement System
Florida
$195K – – –
VOYA Investment Management
48
VOYA Investment Management
Georgia
$195K – – –
Manulife (Manufacturers Life Insurance)
49
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$192K -$5.58K -1,462 -3%
BA
50
BlackRock Advisors
Delaware
$191K -$25.6K -6,711 -13%
1
2
3 4

PGNX Hedge Fund Activity: Q2 2014 in Review

76 of the 3,480 institutional investors tracked by Wall St. Rank reported a position in Progenics Pharmaceuticals Inc (PGNX) for Q2 2014, worth a combined $219M — up 2.7% from $213M a quarter earlier.

Sellers outnumbered buyers: 20 funds closed out of PGNX and 9 opened new positions — a net loss of 11 holders — while 25 trimmed existing stakes and 28 added.

The largest buyer was Broadfin Capital, adding an estimated $4.01M. The largest seller was Taconic Capital Advisors, exiting entirely with an estimated $3.21M sold.

  • 76 institutional investors held Progenics Pharmaceuticals Inc (PGNX) as of Q2 2014, down from 87 in Q1 2014.
  • Funds reported $219M of Progenics Pharmaceuticals Inc stock for Q2 2014, up 2.7% quarter-over-quarter.
  • 9 funds opened new Progenics Pharmaceuticals Inc positions in Q2 2014 and 20 closed out, a net change of -11 holders.
  • The largest Progenics Pharmaceuticals Inc buyer in Q2 2014 was Broadfin Capital, an estimated $4.01M added.
  • The largest Progenics Pharmaceuticals Inc seller in Q2 2014 was Taconic Capital Advisors, an estimated $3.21M sold.

Based on aggregated 13F filings for Q2 2014.